FDA panel votes in favor of Medicines Co's blood clot preventer

April 15, 2015 8:04 PM

25 0

(Reuters) - The Medicines Co's intravenous blood clot preventer can be used in angioplasty procedures, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday.

The panel voted 9-2 to support the approval of the once-rejected injection, cangrelor, for use in some patients undergoing angioplasty, a procedure to widen narrowed or clogged coronary arteries that often includes the use of stents.

Read more

To category page